Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Phase IIb open-label single-arm study of olorofim (F901318) for invasive fungal infections due to resistant fungi
NL-OMON52686Phase 2Active, not recruiting
- Sponsor
- F2G
- Start
- Jul 2018
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 2, open-label, single-arm trial of olorofim in invasive mycoses, invasive aspergillosis (IA), lomentosporiosis and 1 more, sponsored by F2G. Primary endpoint: DRC-adjudicated overall response rate by pathogen at Day 42. Started Jul 2018; status: active, not recruiting.
02
Drugs
olorofim
03
Conditions
invasive mycosesinvasive aspergillosis (IA)lomentosporiosisallescheriosis
Beyond the preview
Go deeper on NL-OMON52686.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NL-OMON52686.